Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05927571
Title A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries ISR | AUS


No variant requirements are available.